Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies
Status:
Completed
Trial end date:
2020-02-20
Target enrollment:
Participant gender:
Summary
Pemetrexed is used in the treatment of non-small cell lung cancer (NSCLC). Its elimination is
mainly renal and its nephrotoxicity requires an interruption of treatment when the CrCLCG
falls below 45 mL / min. Patients with NSCLC frequently have impaired renal function by other
cytotoxic drugs.
The dose adjustment of pemetrexed is performed as a function of body surface area (SC)
without any pharmacokinetic rational. The challenge is to treat patients with renal
insufficiency (RR) with a safe dose, based on CRCL, providing equivalent biological exposure
to patients with preserved renal function.